Yoshikawa, Yuki
Imamura, Michio
Yamauchi, Masami
Hayes, C. Nelson
Aikata, Hiroshi
Okamoto, Wataru
Miyata, Yoshihiro
Okada, Morihito
Hattori, Noboru
Sugiyama, Kazuhiko
Yoshioka, Yukio
Toratani, Shigeaki
Takechi, Masaaki
Ichinohe, Tatsuo
Ueda, Tsutomu
Takeno, Sachio
Kobayashi, Tsuyoshi
Ohdan, Hideki
Teishima, Jun
Hide, Michihiro
Nagata, Yasushi
Kudo, Yoshiki
Iida, Koji
Chayama, Kazuaki
Article History
Received: 11 May 2022
Accepted: 16 November 2022
First Online: 29 November 2022
Declarations
:
: The present study was a single-center, single-arm trial conducted at the Hiroshima University Hospital. This study was carried out in accordance with the Declaration of Helsinki and the.Hiroshima University Hospital Institutional Ethics Committee approved this study (E-2176). The data were analyzed anonymously, and informed consent was obtained in the form of opt-out on the website.
: Not applicable.
: Michio Imamura has received research funding from Bristol-Myers Squibb and AbbVie. Hiroshi Aikata has received honoraria from Eisai and Bayer. Tsutomu Ueda has received research funding from Ono Pharmaceutical. Tatsuo Ichinohe has received honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharma and Kyowa Kirin and research funding from Astellas Pharma, Chugai Pharma, CSL Behring, Eisai, FUJIFILM Wako Chemicals, Kyowa Kirin, Ono Pharma, Pfizer, Nippon Shinyaku, MSD, Otsuka Pharma, Repertoire Genesis Inc., Dainippon Sumitomo Pharma, Taiho Pharma, Takara Bio, Takeda Pharma and Zenyaku Kogyo. Kazuaki Chayama has received honoraria from Bristol-Myers Squibb, MSD K.K., AbbVie, Gilead Science, Dainippon Sumitomo Pharma and Mitsubishi Tanabe Pharma and research funding from Gilead Science, Dainippon Sumitomo Pharma, MSD K.K., AbbVie, Eisai, TORAY, Otsuka Pharma, Chugai Pharma, Takeda Pharma and Roche. Other authors declare no competing interests.